varenicline (CP-526,555)
Sponsors
Pfizer
Conditions
Smoking Cessation
Phase 3
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
CompletedNCT00141206
Start: 2003-05-31End: 2005-04-30Target: 1005Updated: 2007-06-04
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
CompletedNCT00143364
Start: 2003-06-30End: 2005-03-31Target: 1005Updated: 2007-06-04
A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline
CompletedNCT00143299
Start: 2003-10-31End: 2005-03-31Target: 375Updated: 2007-06-04
An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation
CompletedNCT00143325
Start: 2005-01-31End: 2006-06-30Target: 730Updated: 2007-06-04
A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation
CompletedNCT00143286
Start: 2003-04-30End: 2005-03-31Target: 2000Updated: 2007-06-04
Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder
CompletedNCT00644969
Start: 2008-05-31End: 2010-04-30Updated: 2011-04-15